|1.||Gastroesophageal Reflux (GERD)
|2.||Stomach Ulcer (Gastric Ulcer)
|3.||Duodenal Ulcer (Curling's Ulcer)
|5.||Peptic Ulcer (Peptic Ulcers)
|1.||Kinoshita, Yoshikazu: 18 articles (08/2013 - 12/2003)|
|2.||Miwa, Hiroto: 14 articles (08/2013 - 08/2004)|
|3.||Nagahara, Akihito: 9 articles (12/2014 - 08/2005)|
|4.||Asaoka, Daisuke: 9 articles (09/2014 - 08/2004)|
|5.||Murray, Liam J: 9 articles (12/2013 - 05/2006)|
|6.||Hongo, Michio: 9 articles (03/2013 - 01/2008)|
|7.||Anderson, Lesley A: 8 articles (12/2013 - 05/2006)|
|8.||Li, Yan: 8 articles (12/2011 - 01/2007)|
|9.||Ishihara, Shunji: 8 articles (11/2011 - 03/2004)|
|10.||Haruma, Ken: 7 articles (11/2015 - 01/2006)|
|1.||Omeprazole (Esomeprazole)FDA LinkGeneric
04/01/2000 - "Long-term omeprazole therapy (up to 11 years) is highly effective and safe for control of reflux esophagitis."
10/01/1988 - "Omeprazole is a highly effective treatment for peptic esophagitis. "
01/01/2014 - "The use of omeprazole significantly improved sleep disturbances caused by reflux esophagitis, and this effect was not observed when the PPI was withdrawn. "
09/01/2010 - "CYP2C19 polymorphism influences the therapeutic efficacy of omeprazole in the treatment of Iranian patients with erosive reflux esophagitis. "
02/01/1992 - "In doses ranging from 20-60 mg once daily, omeprazole has proved to be effective in the short-term treatment of reflux esophagitis, even in patients resistant to treatment with H2-receptor antagonists. "
|2.||Ranitidine (Zantac)FDA LinkGeneric
09/01/2001 - "Only scattered erosions were observed in antioxidant pre-treated group, but acid suppression by ranitidine was not so effective in decreasing the severity of reflux esophagitis. "
01/01/1997 - "Ranitidine 150 mg bid and 300 mg bid are safe and effective treatments in the prevention of reflux esophagitis relapse."
01/01/1997 - "To compare the efficacy and safety of long term use of ranitidine 150 mg bid, 300 mg bid and placebo in prevention of endoscopic and symptomatic relapse of reflux esophagitis in an international, double-blind, placebo controlled, parallel group study. "
01/01/1997 - "Prevention of relapse in reflux esophagitis: a placebo controlled study of ranitidine 150 mg bid and 300 mg bid."
08/01/1986 - "In a randomized multicentre study 96 patients with mild to moderate types of reflux esophagitis (stages I and II according to Savary-Miller) the effect of 150 mg ranitidine b.i.d. "
|3.||lansoprazole (Prevacid)FDA LinkGeneric
02/01/1998 - "Lansoprazole was safe and effective for the treatment of reflux esophagitis in this trial. "
08/01/2009 - "Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis."
01/01/2008 - "The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study."
09/01/2001 - "[Complementary observational study of the efficacy, tolerance and safety of lansoprazole 15 mg as maintenance therapy of reflux esophagitis in daily medical practice in Belgium (record RU49749/R002]."
02/01/1998 - "This study indicates that the optimum daily dose of lansoprazole for reflux esophagitis is 30 mg."
|4.||Proton Pump InhibitorsIBA
11/01/2003 - "In adult studies, proton pump inhibitors (PPIs) are highly effective in relieving reflux symptoms and healing reflux esophagitis. "
01/01/2013 - "Proton pump inhibitors (PPIs) are widely used as the mainstay of treatment for erosive reflux esophagitis, based on the excellent results obtained in clinical trials. "
08/01/2002 - "Medical therapy with proton pump inhibitors for endoscopically proven reflux esophagitis is a safe and effective treatment option. "
06/01/2001 - "Proton pump inhibitors are not more (and are sometimes even less) effective in non-erosive reflux disease than in reflux esophagitis. "
11/01/2015 - "Proton pump inhibitors are the first-line treatment for reflux esophagitis. "
|5.||Proton Pumps (Proton Pump)IBA
11/01/1997 - "Proton pump inhibitor (PPI) is very effective in the initial treatment of reflux esophagitis. "
01/01/2009 - "Reflux esophagitis, which was seen in five patients, was treated successfully with a proton pump inhibitor. "
12/01/2010 - "Short-term treatment with a proton pump inhibitor (PPI) is effective for healing reflux esophagitis and improving reflux symptoms in pediatric patients. "
03/01/2004 - "Administration of H2 receptor antagonist with proton pump inhibitor is effective for long-term control of refractory reflux esophagitis."
06/01/2004 - "Patients with non-erosive minimal esophageal lesions had similar reflux symptoms comparable to those with mild erosive reflux esophagitis, and reflux symptoms were improved with a short-term proton pump inhibitor. "
|6.||Famotidine (Pepcid)FDA LinkGeneric
02/01/1992 - "Recent data also show that long-term treatment with famotidine seems to be effective in preventing recurrence in most patients with healed reflux esophagitis. "
09/01/1997 - "The results showed that maintenance therapy with famotidine 20 mg twice daily is effective in a large proportion of patients with healed reflux esophagitis, with few adverse effects reported."
12/01/1993 - "Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis."
01/01/1987 - "This study was conducted to determine whether the use of a new H2-antagonist, famotidine, could prevent recurrence of reflux esophagitis among such children. "
01/01/1987 - "Further studies should be conducted to define the role of famotidine in the treatment of reflux esophagitis."
|7.||pantoprazole (Protonix)FDA LinkGeneric
11/01/2000 - "Parenteral pantoprazole is effective in the treatment of reflux esophagitis. "
12/01/2012 - "Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial."
01/01/2012 - "CYP2C19 genotypes determine the efficacy of on-demand therapy of pantoprazole for reflux esophagitis as Los-Angeles grades C and D."
12/01/2012 - "The purpose of this study was to compare the efficacy and safety of S-pantoprazole 20 mg versus pantoprazole 40 mg for treatment of reflux esophagitis. "
12/01/2012 - "The healing rate of reflux esophagitis was 85 % at 4 weeks and 94 % at 8 weeks in the S-pantoprazole group, which did not differ from those in the pantoprazole group (84 and 97 %, respectively). "
|8.||Sucralfate (Carafate)FDA LinkGeneric
09/28/1987 - "These data fail to establish that eight weeks of treatment with sucralfate suspension improves symptoms or heals lesions in reflux esophagitis at a rate significantly greater than placebo. "
06/09/1989 - "The purpose of this study was to determine the efficacy of sucralfate in the treatment of peptic esophagitis in children. "
09/28/1987 - "The efficacy of sucralfate suspension in the treatment of reflux esophagitis was assessed in a multicenter, randomized, double-blind, placebo-controlled trial. "
01/01/1989 - "Efficacy of sucralfate in refractory reflux esophagitis. "
09/28/1987 - "Clinical efficacy of sucralfate in reflux esophagitis. "
|9.||rabeprazole (Aciphex)FDA Link
11/01/2012 - "The symptom score and quality of life in the severe symptoms groups for both reflux esophagitis and non-erosive reflux disease were significantly improved by rabeprazole treatment. "
11/01/2012 - "Only the reflux score was improved by rabeprazole in the reflux esophagitis with mild symptoms group; no therapeutic effect was observed for the non-erosive reflux disease with mild symptoms group. "
04/01/2012 - "Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study."
01/01/2011 - "Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis."
07/15/2001 - "When evaluated by decision analysis over a wide range of assumptions, rabeprazole was comparable to other PPIs in terms of cost and offered improved effectiveness for maintenance therapy of erosive reflux esophagitis."
|10.||Cimetidine (Biomet)FDA LinkGeneric
02/01/1989 - "We conclude that cimetidine is an effective agent for treatment of reflux esophagitis in children. "
01/01/1986 - "This combination is efficacious in the management of chronic reflux esophagitis but, because of frequent side effects, should be reserved for patients refractory to treatment with cimetidine alone."
05/01/1978 - "The efficacy of cimetidine (1.6 g per day) was evaluated using a double blind placebo-controlled trial in 24 patients with moderate or severe peptic reflux esophagitis. "
09/01/1990 - "Efficacy of different doses of cimetidine in the treatment of reflux esophagitis. "
02/01/1989 - "Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study."
01/01/1982 - "Experimental studies of reflux esophagitis following total gastrectomy in rats-pathogenesis and treatment."
01/01/1981 - "In this study, the effect of PANa on the chronic reflux esophagitis in rats induced by total gastrectomy followed by esophagojejunostomy was investigated. "
01/01/2015 - "[Prevention of reflux-esophagitis after gastrectomy]."
06/01/2014 - "A total gastrectomy followed by esophagojejunostomy was performed on rats in order to induce chronic duodenal content reflux esophagitis. "
01/01/2014 - "To evaluate the efficiency and safety of Livodexa monotherapy in patients with reflux esophagitis (RE) after gastric resection or gastrectomy. "
03/01/1993 - "Nissen fundoplication is effective in patients with reflux esophagitis who have adequate esophageal motility."
04/01/1974 - "Proceedings: Nissen fundoplication without crural repair: a cure for reflux esophagitis."
04/01/1993 - "This study evaluates the clinical and endoscopic long-term results of Nissen fundoplication in reflux esophagitis. "
01/01/2011 - "[Fundoplication as prophylaxis of reflux-esophagitis in patients with varicose esophageal veins]."
10/01/2009 - "Reflux esophagitis (preoperative rates: group 1, 74%; group 2, 59%) disappeared in all patients after fundoplication. "
|3.||Drug Therapy (Chemotherapy)
03/01/2006 - "The authors concluded that although symptoms improved in more than half of infants with reflux esophagitis followed longitudinally, esophageal mucosal histology remained abnormal at the 1-yr evaluation in the absence of pharmacotherapy. "
03/01/2006 - "Although symptoms improved in more than half of the infants with reflux esophagitis followed longitudinally for 1 yr without pharmacotherapy, histology remained abnormal."
04/01/1991 - "Comparative efficacy of acid reflux inhibition by drug therapy in reflux esophagitis."
03/01/2006 - "Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy."
03/01/2005 - "Reflux esophagitis secondary to chemotherapy detected by serial FDG-PET."
05/01/2010 - "Roux-en-Y reconstruction is superior to billroth I reconstruction in reducing reflux esophagitis after distal gastrectomy: special relationship with the angle of his."
06/01/2006 - "Thus, duodenogastroesophageal reflux with low gastric acidity is one of the pathogeneses in the development of reflux esophagitis from the present clinical study with patients after distal gastrectomy reconstructed with Billroth I anastomosis."
01/01/2012 - "Thirty-four post-Billroth II distal gastrectomy patients with reflux esophagitis and without erosive and ulcerative lesions of the gastric stump and anastomosis, who had received geviscon monotherapy for 6 weeks, were examined. "
05/01/2006 - "Reflux esophagitis in patients with partial gastrectomy and Billroth I or II reconstruction."
05/01/2006 - "Data on the occurrence of reflux esophagitis and Barrett's esophagus in patients with Billroth I or II resection is sparse. "
08/01/2006 - "Although cases of reflux esophagitis (RE) developing after treatment to eradicate Helicobacter pylori have been discussed in some detail, no reports are available concerning the histologic examination of RE both before and after eradication therapy. "
05/01/1998 - "Patients with reflux esophagitis have rapid relapses after treatment withdrawal. "
11/01/1994 - "Patients with reflux esophagitis have rapid relapses after treatment withdrawal. "
10/01/2010 - "Esophagogastroduodenoscopy revealed acute gastritis with duodenogastric reflux and suspicious reflux esophagitis of minimal change, but there was no significant improvement after treatment and as a result she was admitted to the emergency room. "
09/01/1997 - "Therefore, the efficacy of famotidine 20 mg twice daily was evaluated in an open-label prospective study in 317 patients who had experienced healing of erosive reflux esophagitis after treatment with famotidine; 259 patients completed the study and were assessable according to study protocol. "